Faeth Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
37.3%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$73.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Topline Phase 2 Data Readout for PIKTOR in Advanced Endometrial Cancer | 31 Dec 2026 |
| Interim Phase 1b/2 Data Readout for PIKTOR in HR+/HER2- Advanced Breast Cancer | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
Objective Response Rate (ORR) of PIKTOR in Endometrial Cancer Annually80.0%Target: Maintain high efficacy in larger Phase 2 cohort
Cash Runway and Funding Quarterly200MTarget: Sufficient to fund clinical operations through key readouts
Watch Items
- Phase 2 clinical trial (Study FTH-PIK-201) topline data readout in advanced endometrial cancerTrigger: Second half of 2026Action: Evaluate efficacy (ORR, PFS) and safety profile to support potential registrational pathways.
- Phase 1b/2 clinical trial (Study FTH-PIK-101) interim data readout in HR+/HER2- advanced breast cancerTrigger: Expected in 2027Action: Assess safety and early efficacy signals of the PIKTOR combination regimen.
Research as of 24 Jul 2026